drugset / Trial / NCT06274008

Exparel vs. ACB With Bupivacaine for ACL Reconstruction

NCT06274008

Phase 1 Unknown 96 enrolled Children's Hospital of Orange County
RandomizedParallel-groupDouble-blindSupportive care

Summary

Opioid misuse and addiction among children and adolescents is an increasingly concerning problem. Post-surgical opioid prescriptions for commonly performed surgeries such as anterior cruciate ligament reconstruction (ACLR) increase opioid exposure in young athletes. The purpose of the current study is to determine if extended-release Bupivacaine Liposome Injectable Suspension (Exparel) is effective in decreasing at home narcotic consumption compared to standard Bupivacaine Adductor Canal Block for Anterior Cruciate Ligament (ACL) reconstruction/reconstruction for the surgical treatment of adolescents with ACL tears and concomitant pathology i.e. meniscus / cartilage injury/tear.

Timeline

Start
2023-10-12
Primary completion
2024-10-30
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Background Bupivacaine Other / unclassified 10 ml Other
Background Bupivacaine Other / unclassified 0.5 % Other
Background Bupivacaine Other / unclassified 10 ml Other

Indications